Results 211 to 220 of about 4,621,354 (401)

Complement Activation in Pemphigus

open access: yesJournal of Investigative Dermatology, 1980
Robert E. Jordon, Robert E. Jordon
openaire   +3 more sources

Development of 4T1 breast cancer mouse model system for preclinical carbonic anhydrase IX studies

open access: yesFEBS Open Bio, EarlyView.
Carbonic anhydrase IX (CAIX) is a well‐recognised therapeutic target and prognostic biomarker in cancer. We developed and characterised a robust murine breast cancer model system that is suitable for CAIX studies in vitro and in vivo—it comprises both CAIX‐positive and CAIX‐negative controls and provides a solid platform for the comprehensive ...
Zane Kalniņa   +13 more
wiley   +1 more source

GDP‐fucose transporter SLC35C1: a potential regulatory role in cytosolic GDP‐fucose and fucosylated glycan synthesis

open access: yesFEBS Open Bio, EarlyView.
The inactivation of SLC35C1 (GDP‐fucose transporter) and enzymes involved in GDP‐fucose biosynthesis was studied. Fucose supplementation increases the level of GDP‐fucose to abnormal, millimolar values in the absence of the TSTA3 protein and SLC35C1 in contrast to the GMDS/SLC35C1 double mutant.
Edyta Skurska, Mariusz Olczak
wiley   +1 more source

Identifying prognostic targets in metastatic prostate cancer beyond AR

open access: yesFEBS Open Bio, EarlyView.
Genome‐wide functional screens combined with a large gene expression database and clinical outcomes can identify new therapeutic vulnerabilities in prostate cancer. Eight potentially druggable targets demonstrated strong dependency in cell lines, were associated with worse prognosis clinically, and showed evidence of protein expression in prostate ...
Emily Feng   +13 more
wiley   +1 more source

Comprehensive end‐to‐end dosimetry audit for stereotactic body radiotherapy in spine, lung, and soft tissue

open access: yesJournal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose To create and conduct a comprehensive onsite end‐to‐end dosimetry audit to assess treatment accuracy of spine, lung, and soft tissue Stereotactic Body Radiotherapy (SBRT) across Australian and New Zealand (ANZ) radiotherapy centers. Methods The Australian Clinical Dosimetry Service (ACDS) anthropomorphic thorax phantom underwent a CT ...
Maddison Shaw   +8 more
wiley   +1 more source

Cerebello‐Prefrontal Connectivity Underlying Cognitive Dysfunction in Spinocerebellar Ataxia Type 2

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Spinocerebellar ataxia type 2 (SCA2) is a hereditary cerebellar degenerative disorder, with motor and cognitive symptoms. The constellation of cognitive symptoms due to cerebellar degeneration is named cerebellar cognitive affective syndrome (CCAS), which has increasingly been recognized to profoundly impact patients' quality of life;
Ami Kumar   +7 more
wiley   +1 more source

Complement reaction in leprosy. Activation by potassium Iodide

open access: hybrid, 1933
J. M. Gomes, P.C. de Azevedo Antunes
openalex   +1 more source

Very High‐Frequency Oscillations in Mesial Temporal Lobe Epilepsy: Identifying the Epileptogenic Zone

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate the reliability of very high‐frequency oscillations (VHFOs, 500–2000 Hz) as biomarkers in identifying the epileptogenic zone (EZ) in mesial temporal lobe epilepsy (MTLE) patients. Methods We reviewed 19 MTLE patients who underwent stereo‐electroencephalography‐guided radiofrequency thermocoagulation.
Stéphane Jean   +10 more
wiley   +1 more source

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy